Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119701) titled 'Effects of Esketamine on Overall Analgesic Benefits and Postoperative Depression in Patients Undergoing Pancreatic Resection for Pancreatic Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial' on March 2.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The First Affiliated Hospital of Soochow University
Condition:
Pancreatic cancer
Intervention:
Esketamine Group:Intravenous esketamine at a dose of 0.15 mg/kg/h, starting from before skin incision after anesthesia induction, continuing until wound closure or up to 4 hours (total dose not exceeding 0.6 mg/kg)
R...